What the MIT discovery reveals about APOE4, myelin and longevity
Recent work from the Picower Institute for Learning and Memory at MIT shows that the APOE4 variant suppresses Wnt signaling in oligodendrocytes, causing lipid-droplet accumulation and defective myelination. Restoring Wnt activity—particularly by inhibiting GSK3β—rescues myelin formation in cell cultures, organoids and APOE4-mouse models, offering a concrete molecular target for future interventions.
According to MIT News – Biology | Genetics | biophysics, the study published on October 15 in Cell Stem Cell demonstrates that APOE4-associated myelin defects stem from reduced beta-catenin and excess GSK3β, which together blunt Wnt signaling. Inhibiting GSK3β with the small molecule CHIR99021 reduced lipid droplets, increased myelination, and promoted axon growth in APOE4 organoids and mice.
Background: APOE4, oligodendrocytes and the myelin sheath
APOE4 is the strongest genetic risk factor for late-onset Alzheimer’s disease. While much attention has focused on neuronal amyloid and tau pathology, oligodendrocytes—the brain cells that wrap axons with a fatty insulating layer called myelin—are also profoundly affected. Myelin is essential for rapid electrical conduction and for protecting neurons from metabolic stress. When oligodendrocytes fail to produce adequate myelin, neural circuits slow down, and the brain becomes vulnerable to degeneration.
The MIT team, led by Picower Professor Li-Huei Tsai and graduate researcher Leyla Akay PhD ’25, previously showed that APOE4 carriers accumulate lipid droplets within oligodendrocytes, a sign that the cells are mis-routing fatty resources away from myelin production. The new study digs deeper, pinpointing the Wnt pathway as the critical bottleneck.
How the researchers uncovered the Wnt connection
Two complementary strategies converged on the same answer:
- Genome-wide CRISPR screen: Using CRISPR gene editing, the team knocked out each protein-coding gene in human APOE4 oligodendrocyte cultures. Loss of genes that normally boost Wnt signaling led to lipid-droplet buildup, while loss of genes that suppress Wnt also produced the same phenotype, indicating that balanced Wnt activity is essential.
- Chromatin accessibility (ATAC-seq) analysis: By comparing APOE4-carrying cells to those with the neutral APOE3 variant, the researchers found that DNA regions controlling Wnt-promoting genes were less open for transcription in APOE4 samples. This epigenetic restriction mirrored the CRISPR findings.
Both approaches highlighted a dysregulation of Wnt signaling, a pathway already known to guide cell fate, proliferation and myelin formation during development.
The molecular culprits: beta-catenin and GSK3β
Wnt signaling hinges on a tug-of-war between beta-catenin, which activates the pathway, and glycogen synthase kinase-3 beta (GSK3β), which phosphorylates beta-catenin and marks it for degradation. In APOE4 oligodendrocytes, the MIT group observed two key changes:
- Reduced expression of beta-catenin, weakening the positive arm of Wnt signaling.
- Elevated levels of GSK3β, strengthening the inhibitory arm.
These shifts tip the balance toward Wnt suppression, leaving oligodendrocytes unable to channel lipids into myelin and instead storing them as droplets.
Proof-of-concept: GSK3β inhibition restores myelin
To test whether rebalancing the pathway could rescue myelination, the scientists used two pharmacological tools:
- Dif3: A chemical that raises GSK3β activity. When applied to APOE3 oligodendrocytes, Dif3 increased lipid droplets, confirming that excess GSK3β is sufficient to disrupt myelin metabolism.
- CHIR99021: A selective GSK3β inhibitor. In APOE4 oligodendrocytes, CHIR99021 dramatically reduced droplet accumulation. In three-dimensional organoid cultures that combined APOE4 oligodendrocytes with neurons, the inhibitor boosted myelin sheath formation and encouraged axon extension, visible as increased magenta-stained axon growth.
Extending the experiment to an in-vivo model, the team treated APOE4 mice engineered to develop tau pathology with CHIR99021. Treated animals showed fewer lipid droplets in the hippocampus—a region critical for memory—and exhibited enhanced myelination relative to untreated controls.
Implications for healthy longevity and disease risk
Myelin integrity is not only a determinant of cognitive speed; it also influences overall brain health and resilience to neurodegeneration. The MIT findings suggest that APOE4 carriers may experience accelerated myelin decline, compounding the well-known Alzheimer’s risk. From a longevity perspective, preserving myelin could extend healthspan by maintaining neural efficiency, reducing the burden of age-related cognitive decline, and possibly delaying the onset of dementia.
Because the study identifies a drug-gable target (GSK3β) and a clear molecular readout (lipid-droplet burden, myelin thickness), it opens a pathway for precision-medicine approaches. Future clinical trials could explore GSK3β inhibitors—already under investigation for other neuro-psychiatric conditions—as adjuncts to lifestyle or genetic risk-reduction strategies.
Key take-aways for personalized health strategies
While the research is still at the pre-clinical stage, individuals interested in mitigating APOE4-related risks can consider the following evidence-based actions, which align with broader longevity science:
- Maintain a diet rich in omega-3 fatty acids (e.g., fatty fish, walnuts) to support myelin synthesis.
- Engage in regular aerobic and resistance exercise, both shown to promote oligodendrocyte health.
- Monitor cognitive health with periodic neuropsychological testing, especially if a family history of Alzheimer’s exists.
- Stay informed about emerging clinical trials targeting GSK3β or Wnt signaling pathways.
- Consider genomic testing to confirm APOE status, enabling tailored preventive measures.
Future directions and unanswered questions
The MIT study raises several avenues for further investigation:
- How does chronic GSK3β inhibition affect other brain cell types, such as neurons and astrocytes?
- What is the long-term impact of restored myelination on cognitive performance in APOE4 carriers?
- Can peripheral biomarkers (e.g., blood-based lipid profiles) reliably reflect central myelin health?
- How does Wnt signaling intersect with tau phosphorylation, another hallmark of Alzheimer’s pathology?
Addressing these points will be essential before any therapeutic can move from bench to bedside.
FAQ
What is the main discovery reported by MIT?
The researchers identified that APOE4 suppresses Wnt signaling in oligodendrocytes, leading to lipid-droplet accumulation and impaired myelination, and that inhibiting GSK3β can restore myelin formation.
Why does myelin matter for longevity?
Myelin ensures rapid neural communication and protects axons from metabolic stress; its decline is linked to slower cognition and higher risk of neurodegenerative disease, which can shorten healthspan.
What experimental models were used?
Human APOE4 oligodendrocyte cultures, three-dimensional organoids combining oligodendrocytes and neurons, and APOE4 mouse models that also carry tau pathology.
Which molecules were manipulated to test the hypothesis?
Beta-catenin (a Wnt activator) and GSK3β (a Wnt inhibitor) were examined; the GSK3β inhibitor CHIR99021 was used to rescue myelination, while the GSK3β activator Dif3 induced lipid droplets.
Is there a therapeutic product available now?
No. The study provides proof-of-concept evidence; GSK3β inhibitors are still in pre-clinical testing for this specific application.
How might this research affect people who carry APOE4?
It suggests a molecular mechanism behind their increased Alzheimer’s risk and points to a potential drug target that could one day be incorporated into personalized prevention plans.
What funding supported the work?
The National Institutes of Health, the Robert and Renee E. Belfer Family Foundation, the Manthripragada McManama Alzheimer’s Fund, the CAMA Seed Fund, the J. Crayton Pruitt Foundation, Joseph P. DiSabato and Nancy Sakamoto, and the Freedom Together Foundation.
Conclusion
The MIT investigation illuminates a concrete biochemical link between the APOE4 allele and disrupted myelin production, centering on Wnt pathway suppression and GSK3β overactivity. By demonstrating that pharmacological inhibition of GSK3β can reverse lipid accumulation and restore myelination in both organoid and mouse models, the study offers a promising target for future precision-medicine interventions. As the field moves toward integrating genomic risk with actionable therapies, this work underscores the importance of protecting myelin health as a cornerstone of healthy aging and longevity.
⌚ Try wearable syncing — 10 days free
Connect a tracker and get a real picture of your health right now. All data is anonymous.
